Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Jeng-Sen Tseng,1,2 Tsung-Ying Yang,2 Kun-Chieh Chen,1,2 Kuo-Hsuan Hsu,1,3 Chong-Jen Yu,4 Wei-Yu Liao,4 Chi-Ren Tsai,5,6 Meen-Hsin Tsai,2,7 Sung-Liang Yu,8–11 Kang-Yi Su,8,12 Jeremy JW Chen,1 Hsuan-Yu Chen,7 Gee-Chen Chang1,2,13–151Institute of Biomedical Sciences, National Chung...

Full description

Bibliographic Details
Main Authors: Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC
Format: Article
Language:English
Published: Dove Medical Press 2014-05-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/prior-egfr-tyrosine-kinase-inhibitor-therapy-did-not-influence-the-eff-a16967

Internet

http://www.dovepress.com/prior-egfr-tyrosine-kinase-inhibitor-therapy-did-not-influence-the-eff-a16967

Similar Items